International Stem Cell announced that it intends to start the phase 1/2a clinical study of its cell therapy for the treatment of Parkinson's disease in Australia within the next few months. The company has completed the required preclinical studies for the phase 1/2a clinical study of the clinical product, ISC-hpNSC, for the treatment of Parkinson's disease. This TGA submission includes non-clinical studies evaluating the safety and tolerability of the clinical product, ISC-hpNSC, in different animal species, including non-human primates, along with the chemistry and manufacturing controls and a summary of the clinical study design, according to the company.